EFFICACY AND SAFETY OUTCOMES OF RANDOMIZED CONTROLLED OPEN LABEL TRIALS INVESTIGATING COMBINATION OF BIOWIN AND BIOWN IN COVID-19 PATIENTS

Dr. D. M. Ravichand* and Dr. K. Sunil Naik

ABSTRACT

COVID-19 is the second pandemic of the twenty-first century, with over a hundred million infections and over two million deaths too far. It's a new Coronaviridae strain called Severe Acute Respiratory Distress Syndrome Coronavirus-2 (SARS-CoV-2). It's the 7th known coronavirus to cause sickness in humans, following the Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Distress Syndrome Coronavirus-1 (SARS-CoV-1) (SARS). Most COVID-19 patients, particularly the elderly and immune compromised, experience flu-like symptoms such as a dry cough and a headache. Because current COVID-19 treatment choices are limited, especially for this vulnerable elderly group. Pneumonia, acute respiratory distress syndrome, septic shock, and cardiovascular symptoms are the most prevalent consequences. SARS-CoV-2 is spread mostly through respiratory droplets, which are released into the air when an infected person coughs or sneezes, or in the form of fomites on surfaces. Hand cleanliness, social distance, and personal protective equipment (such as masks) remain the most effective safeguards. Patient management includes supportive care and alternative measures, with a focus on maintaining respiratory functionas main criteria. Therapy with biowin and biown and its combination appear to be most promising and effective in COVID 19 patients. Additionally, accelerated vaccination efforts have taken place internationally, with several promising vaccinations being mass deployed. The nutraceutical supplementation in combating the COVID-19 has gained substantial attention, however to date little is known about the real-life consequences of impairment in this unique patient population. The aim of this study is to evaluate the safety, efficacy and quality of life (QOL) of deficits experienced by patients with COVID-19 infection. The study design is of prospective and a sample size of 50 with inclusion criteria of 18 to 58 years subjected were included in the study. A longitudinal web-based nationwide questionnaire survey of adults with COVID-19 was conducted to assess the qualityof life of patients. Impact on QOL was substantial with 96% of subjects reporting at least one of the defined deficits, and over 75% reporting various assessed parameters showing the impact on their quality of life. Many COVID-19 infected people are asymptomatic or experience moderate symptoms and recover without medical intervention. However, older people and those with comorbid hypertension, diabetes, obesity, or heart disease are at higher risk of mortality. We propose that normalcy could be restored using a combinational supplementation of Biowin and Biown in COVID19 patients. Therefore, it can be concluded the neutraceutical supplement therapy is the best option by improving the respiratory function and ultimately promoting survival in COVID-19 patients that develop severe forms of this devastating disease.

Keywords: COVID-19; Coronavirus; Global & Public Health; Infectious Diseases; Pandemic.